If you have been reading about Certificate of analysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-15. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Primary reported target | Hepatocyte growth factor/c-Met signaling | Findings mainly from cell and animal studies. |
| Related endogenous peptide | Angiotensin IV | Dihexa is described as a stabilized analog. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for purity assessment. |
| Identity confirmation | Mass spectrometry | Provides a molecular mass check. |
| Regulatory status | Not approved for human use | Sold as a research chemical in many jurisdictions. |
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
A stereogenic center (or stereocenter) is an atom such that swapping the positions of two ligands (connected groups) on that atom results in a molecule that is stereoisomeric to the original. For example, a common case is a tetrahedral carbon bonded to four distinct groups a, b, c, and d (Cabcd), where swapping any two groups (e.g., Cbacd) leads to a stereoisomer of the original, so the central C is a stereocenter. Many chiral molecules have point chirality, namely a single chiral stereogenic center that coincides with an atom. This stereogenic center usually has four or more bonds to different groups and may be carbon (as in many biological molecules), phosphorus (as in many organophosphates), silicon, or a metal (as in many chiral coordination compounds). However, a stereogenic center can also be a trivalent atom whose bonds are not in the same plane, such as phosphorus in P-chiral phosphines (PRR′R″) and sulfur in S-chiral sulfoxides (OSRR′), because a lone-pair of electrons is present instead of a fourth bond.
== Diseases == There are some indications that NatB might N-terminally acetylate α-synuclein, a protein involved in Parkinson's disease. α-synuclein is a potential match for NatB enzymatic activity, as the protein starts with MD. N-terminal acetylation of α-synuclein has been found to stabilize the protein and regulate the neuronal toxicity level. NatB is also found to be essential for shutoff activity of PA-X, a protein from Influenza A virus. PA-X influences the gene expression and the immune response in a host, and NatB contributes by shutting off the RNA replication of the virus, even though the mechanism behind this is not known. There are some cancer related phenotypes where NAA20 expression was upregulated in hepatocarcinoma and liver cancer. NAA20 expression was also upregulated in by triple-negative breast cancer cells (TNBC), and studies showed that NAA20 could be targeted by TNBC cells to promote cell proliferation by activating EGFR signaling via Rab5A. Knockdown of NAA20 in vivo showed a decrease in tumor growth There are recent studies involving patients having mutations in the NAA20 gene, which were discovered by genetic screening. These patient mutations were found to affect the enzymatic properties of NatB thus probably being the cause of the various symptoms affecting their lives. These mutations are rare, involving only seven individuals from three different families reported so far, but all various mutations that have been found are on the NAA20 gene.
==== Criminal sanctions ==== Money laundering has been criminalized in the United States since the Money Laundering Control Act of 1986. The law, contained at section 1956 of Title 18 of the United States Code, prohibits individuals from engaging in a financial transaction with proceeds that were generated from certain specific crimes, known as "specified unlawful activities" (SUAs). The law requires that an individual specifically intends to make the transaction to conceal the source, ownership or control of the funds. There is no minimum threshold of money and no requirement that the transaction succeeded in actually disguising the money. A "financial transaction" has been broadly defined, and need not involve a financial institution, or even a business. Merely passing money from one person to another, with the intent to disguise the source, ownership, location or control of the money, has been deemed a financial transaction under the law. The possession of money without either a financial transaction or an intent to conceal is not a crime in the United States. Besides money laundering, the law contained in section 1957 of Title 18 of the United States Code, prohibits spending more than US$10,000 derived from an SUA, regardless of whether the individual wishes to disguise it. It carries a lesser penalty than money laundering, and unlike the money laundering statute, requires that the money pass through a financial institution.
The back corridor, also visible today, is quite unusual, as its vault is trabeated, formed of three flat longitudinal surfaces, on which figures of devatas are aligned like a deck of cards. On the bench along the back wall, stood a colossal reclining Buddha image in a scene of the Parinirvana, with elegant flying devatas hovering over the Buddha. Remains of female statues seated on the back bench were visible, with, at their, feet the bust of a man-elephant. The style of the paintings in this cave, especially in the side and back corridors is very elegant and "painterly", with sophisticated shading of the bodies to express sculptural volume. It is quite similar to the style of the Cave of the Hippocampi (Cave 118), and may belong to the same school. This refined style contrasts with the style of panels in the cella, the "Cowherd Nanda", which is much bolder, using intense colors (browns, greens and oranges), thicker lines and simpler patterns. This divergence suggests that the "Cave of the Statues" may be transitional between these two early styles. Later caves such as the Cave of the Musicians point to an even more different style, using vivid colors and Ligne claire sharp lines to delineate body shapes together with the abundant use of intense blue pigments, with different roots inspired by the Western art of the 4th century CE.
However, White House deputy chief of staff Stephen Miller said that Trump had a red line to not allow Iran to develop nuclear weapons, and he will use force if necessary to accomplish that. On April 25, Trump announced cancellation of an envoy trip for further rounds of talks with Iranian leaders at Islamabad, citing what he alleged was divisions within Iranian leadership.
Sources: en.wikipedia.org
There are 21 known isotopes of sodium (11Na), ranging from 17Na to 39Na (except for 36Na and 38Na), and five isomers. 23Na is the only stable (and the only primordial) isotope, making sodium a monoisotopic (and mononuclidic) element. Sodium has two radioactive cosmogenic isotopes (22Na, with a half-life of 2.6019 years and 24Na, with a half-life of 14.956 hours). With the exception of those two isotopes, all other isotopes have half-lives under a minute, most under a second. Acute neutron radiation exposure (e.g., from a nuclear criticality accident) converts some of the stable 23Na in human blood plasma to 24Na. The neutron radiation dose absorbed by the patient can be assessed by measuring the concentration of the radioisotope. 22Na is a positron-emitting isotope with a relatively long half-life, about 2.6 years. It is used to create test-objects and point-sources for positron emission tomography.
Enavogliflozin (DWP16001/GCC5694A) is a selective SLC5A2 and SGLT2 inhibitor developed to treat diabetes and obesity. It was developed by GC Pharma and Daewoong Pharmaceutical. Enavogliflozin has been approved for clinical use in South Korea, and Ecuador, and applied for approval in Brazil, Mexico, Peru, and Colombia. In a meta-analysis published by Dutta et al. analysing data from 4 trials over 6 months of clinical use, enavogliflozin was well tolerated and was found to be effective for managing type 2 diabetes and may be superior to dapagliflozin with regard to certain clinical aspects
== Chemical properties == It reacts with cesium fluorosulfonate and silver fluorosulfonate to produce the divalent silver compound CsAg(SO3F)3. Iodine(I) fluorosulfonate can be obtained from iodine and peroxydisulfuryl difluoride:
===== MeSH D08.811.277.151 – aminohydrolases ===== MeSH D08.811.277.151.300 – gtp cyclohydrolase MeSH D08.811.277.151.350 – guanine deaminase MeSH D08.811.277.151.418 – methenyltetrahydrofolate cyclohydrolase MeSH D08.811.277.151.486 – nucleoside deaminases MeSH D08.811.277.151.486.075 – adenosine deaminase MeSH D08.811.277.151.486.250 – cytidine deaminase MeSH D08.811.277.151.486.625 – cytosine deaminase MeSH D08.811.277.151.653 – nucleotide deaminases MeSH D08.811.277.151.653.060 – amp deaminase MeSH D08.811.277.151.653.200 – dcmp deaminase
Sources: en.wikipedia.org
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.
Reverse-phase high-performance liquid chromatography is commonly used to assess purity. Mass spectrometry is used to confirm molecular identity. These methods are typical for synthetic peptides and research chemicals.
Dihexa is not approved as a drug in major jurisdictions. It is often sold as a research chemical, which is not the same as a medicine. Its legal status can vary by country and may change.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.